Fertility and Sterility
Volume 83, Issue 6 , Pages 1607-1611, June 2005

Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?

  • Bart C.J.M. Fauser, M.D.

      Affiliations

    • Department of Reproductive Medicine, University Medical Center, Utrecht, The Netherlands
    • Corresponding Author InformationReprint requests: Bart C.J.M. Fauser, M.D., University Medical Center, Department of Reproductive Medicine, P.O. Box 85500, Utrecht 3508 GA, The Netherlands (FAX: 31-30-250-5433).
    • ,
  • Paul Devroey, M.D.

      Affiliations

    • Center of Reproductive Medicine, Dutch-Speaking Free University Brussels, Brussels, Belgium

Received 1 October 2004; received in revised form 16 February 2005; accepted 16 February 2005.

The use of GnRH antagonist rather than agonist cotreatment during ovarian hyperstimulation for IVF is not widely accepted. Possible benefits, current shortcomings, and avenues for future development are discussed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The opinions and commentary expressed in Editor’s Corner articles are solely those of the author. Publicaiton does not imply endorsement by the Editor or American Society for Reproductive Medicine.

PII: S0015-0282(05)00549-2

doi:10.1016/j.fertnstert.2005.02.011

Fertility and Sterility
Volume 83, Issue 6 , Pages 1607-1611, June 2005

Article Tools